The 17 most recent market catalysts affecting $QNRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 55
CCORF Maintains Buy Rating on Quoin Pharmaceuticals
The filing indicates that Whitney Ijem of CCORF reaffirmed a 'buy' rating for Quoin Pharmaceuticals (QNRX) and maintained an $18 price target on November 9, 2026. This action signa…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 85
Quoin Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Update
Quoin Pharmaceuticals reported positive interim data from its Phase 2/3 clinical trial for QRX003, a key pipeline asset for Netherton Syndrome. This positive clinical update signif…
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 55
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results
Quoin Pharmaceuticals has scheduled the release of its third-quarter 2026 financial results and a corporate update for November 5, 2026. This is a standard quarterly reporting even…
Oct 20, 2026
Corporate Catalyst
Neutral
Impact 75
Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
Quoin Pharma has published a peer-reviewed paper on QRX003, highlighting its mechanism of action and, crucially, a case report of a pediatric patient with Netherton Syndrome who ex…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
Canaccord Genuity initiating coverage on Quoin Pharmaceuticals with a 'Buy' rating and an $18 price target is a significant event for the company. Analyst coverage, especially with…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 65
Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome
Quoin Pharmaceuticals' QRX003 has been granted Orphan Drug Designation by the EMA for Peeling Skin Syndrome. This is a significant regulatory milestone as it provides incentives li…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 65
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14
BTIG analyst Jeet Mukherjee has initiated coverage on Quoin Pharmaceuticals (QNRX) with a 'Buy' rating and a $14 price target. This event is significant for QNRX as new analyst cov…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 65
Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
Quoin Pharmaceuticals announced that a manuscript detailing its investigational drug QRX003 for Netherton Syndrome, including a positive pediatric compassionate-use case report, ha…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Lake Street analyst Thomas Flaten has initiated coverage on Quoin Pharmaceuticals (QNRX) with a 'Buy' rating and a $20 price target. This event is significant for QNRX as new analy…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Quoin Pharmaceuticals Says FDA Granted Fast Track Designation To QRX003 For Peeling Skin Syndrome
The FDA's Fast Track designation for QRX003 is a significant positive catalyst for Quoin Pharmaceuticals (QNRX). This designation aims to expedite the development and review of dru…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 95
QNRX shares are trading higher after the company announced interim Phase 2/3 results showing QRX003 met the primary and key secondary endpoints with statistical significance, along with itch reduction and no serious adverse events.
The successful interim Phase 2/3 results for QRX003 are a major positive catalyst for QNRX. Meeting primary and key secondary endpoints with statistical significance, along with it…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 95
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Quoin Pharmaceuticals (QNRX) experienced a substantial stock surge due to two major announcements. First, positive interim data from its Phase 2/3 trial for QRX003 in Netherton Syn…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 85
Quoin Pharmaceuticals Said Key Secondary Endpoint Of Global Impression of Change Also Achieved Statistical Significance At Week 12
The achievement of statistical significance for a key secondary endpoint, the Global Impression of Change, at week 12 is a strong positive indicator for Quoin Pharmaceuticals' drug…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 85
Quoin Pharmaceuticals Announced Interim Analysis Of First Six Patients To Complete 12 Weeks Of Treatment Met Pre-Specified Alpha Adjusted Target For Primary Endpoint With Statistical Significance
The positive interim analysis of a clinical trial's primary endpoint with statistical significance is a major de-risking event for Quoin Pharmaceuticals. This suggests a high proba…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
Quoin Pharmaceuticals Announced That It Has Entered Into A Securities Purchase Agreement With New And Existing Healthcare-focused Institutional Investors To Raise Up To Approximately $50M In Gross Proceeds
This capital raise is a significant positive for Quoin Pharmaceuticals (QNRX), as it provides essential funding for its ongoing research, development, and operational expenses. The…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 75
Quoin Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 results.
The headline indicates a direct negative impact on Quoin Pharmaceuticals (QNRX) due to its poor Q2 earnings. This is a significant corporate catalyst, as earnings reports are key p…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 92
Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate
Quoin Pharmaceuticals (QNRX) announced its Q2 earnings, reporting a loss of $(1.90) per share, which was 18.01% worse than the analyst consensus estimate of $(1.61). This substanti…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.